Silence Therapeutics (SLN) Common Equity (2018 - 2026)
Silence Therapeutics (SLN) posted Common Equity of $49.4 million for Q1 2026, down 20.71% sequentially from $62.3 million in Q4 2025, and down 56.18% YoY from $112.7 million in Q1 2025.
Silence Therapeutics (SLN) Common Equity (2018 - 2026) Analysis & Trends
Silence Therapeutics has reported Common Equity for 9 years, with the latest figure at $49.4 million in Q1 2026.
- Quarterly Common Equity fell 56.18% year-over-year to $49.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.4 million (down 56.18% YoY) and the FY2025 annual result came in at $62.3 million, down 53.51% from the prior year.
- Common Equity eased to $49.4 million in Q1 2026 per SLN's latest filing, from $62.3 million in the prior quarter.
- Over five years, Common Equity peaked at $156.8 million in Q1 2024 and troughed at $21.2 million in Q4 2023.
- A 5-year average of $90.9 million and a median of $94.2 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2026: Common Equity jumped 533.33% in 2024, then sank 56.18% in 2026.
- Over 5 years, Common Equity stood at $25.9 million in 2022, then fell by 18.26% to $21.2 million in 2023, then surged by 533.33% to $134.0 million in 2024, then tumbled by 53.51% to $62.3 million in 2025, then declined by 20.71% to $49.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $49.4 million, $62.3 million, and $74.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 38.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.47 Mn |
| Mar 31, 2026 | 49.40 Mn |
| Dec 31, 2025 | 62.30 Mn |
| Sep 30, 2025 | 74.06 Mn |
| Jun 30, 2025 | 94.16 Mn |
| Mar 31, 2025 | 112.74 Mn |
| Dec 31, 2024 | 134.02 Mn |
| Sep 30, 2024 | 126.70 Mn |
| Jun 30, 2024 | 142.53 Mn |
| Mar 31, 2024 | 156.76 Mn |
| Dec 31, 2023 | 21.16 Mn |
| Dec 31, 2022 | 25.89 Mn |
| Dec 31, 2021 | 11.49 Mn |
| Dec 31, 2020 | 11.96 Mn |
| Dec 31, 2019 | 26.88 Mn |
| Dec 31, 2018 | 45.11 Mn |